Premium
Green tea constituent epigallocatechin‐3‐gallate selectively inhibits COX‐2 without affecting COX‐1 expression in human prostate carcinoma cells
Author(s) -
Hussain Tajamul,
Gupta Sanjay,
Adhami Vaqar M.,
Mukhtar Hasan
Publication year - 2004
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.20629
Subject(s) - lncap , epigallocatechin gallate , prostate cancer , cancer , medicine , cancer prevention , cancer research , prostate , cancer cell , pharmacology , polyphenol , biology , biochemistry , antioxidant
Abstract Overexpression of cyclooxygenase (COX)‐2 has been implicated in many pathologic conditions, including cancer. One practical inference of this finding is that sustained inhibition of COX‐2 could serve as a promising target for prevention or therapy of cancer. Conventional nonsteroidal antiinflammatory drugs (NSAIDs) and recently developed COX‐2‐specific inhibitors have shown considerable promise in prevention of some forms of human cancer; however, its application is limited due to severe toxic side effects on normal cells. Therefore, there is a need to define novel, nontoxic dietary constituents with proven chemopreventive effects through other pathways that also possess COX‐2 but not COX‐1 inhibitory activity. Recent studies on green tea and its major polyphenolic constituent (‐)epigallocatechin‐3‐gallate (EGCG) have established its remarkable cancer preventive and some cancer therapeutic effects. Here, we show that EGCG inhibits COX‐2 without affecting COX‐1 expression at both the mRNA and protein levels, in androgen‐sensitive LNCaP and androgen‐insensitive PC‐3 human prostate carcinoma cells. Based on our study, it is tempting to suggest that a combination of EGCG with chemotherapeutic drugs could be an improved strategy for prevention and treatment of prostate cancer.